According to The Fly, in a latest note to investors, a research analyst has provided a rating update for the CRH Medical (CRH). Cantor Fitzgerald’s analyst Joseph France reiterates their Hold rating on the shares.
France commented:
“We are reiterating our Neutral rating, but adjusting our 2018-19 outlook and raising our price target to C$3.50 from C$3, to reflect recent acquisitions and the company’s 3Q18 performance. CRH completed two acquisitions (worth C$9.2 million) during the quarter, bringing the year-to-date total to C$25 million and implying C$8 million of acquisitions in 4Q18. The company continues to develop its Managed Anesthesia Care (MAC) program and increase synergies between its Anesthesia and O’Regan businesses. We continue to believe that the company’s outlook depends primarily upon on its ability to partner with prominent GI groups in large markets, and acquire and integrate new practices, while enhancing their revenue cycles management (RCM) capabilities.”
According to TipRanks.com, France is a 5-star analyst with an average return of 10.2% and a 56.9% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and Addus Homecare Corp.
Read also: Here’s Why AcelRx Pharmaceuticals (ACRX) Stock Skyrocketed Today
Currently, the analyst consensus on CRH Medical is a Strong Buy with an average price target of C$5.92.
CRH Medical’s market cap is currently C$306.7M and has a P/E ratio of 37.7. The company has a Price to Book ratio of 3.28.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Monday at C$4.21.
